Treatment
CD19 CAR-T cells clinical trials
We’re tracking 195 recruiting studies that include CD19 CAR-T cells, each written for real people, not researchers, below.
Recruiting studies
- NCT05436509RecruitingPhase 1/Phase 2
CD19/79b CAR-T therapy for certain B-cell cancers
This early-phase study tests a one-time engineered immune-cell treatment (CAR-T) made to recognize CD19 and CD79b on certain cancer cells. It may help people with specific B-cell cancers, but you must meet several health and infection-safety requirements to join.
Shenzhen, GuangdongAges 6 months–75 years - NCT04016129RecruitingPhase 1/Phase 2
CAR-T therapy for certain B-cell blood cancers
This trial tests a lab-made immune therapy called CAR-T that targets specific markers on B-cell leukemia/lymphoma cells. It may help people whose cancer has returned or did not respond after earlier CD19 CAR-T, by attacking the cancer cells using added targeting.
Shenzhen, GuangdongAges 6 months–75 years - NCT07003295RecruitingPhase 2
Glofitamab for mantle cell lymphoma that returned after CAR-T
This trial tests a new drug, glofitamab, for mantle cell lymphoma that came back or didn’t respond after CAR-T cell therapy. It aims to see if glofitamab can shrink or control the lymphoma.
Duarte, CaliforniaAges 18 years+ - NCT06238648RecruitingPhase 2
Epcoritamab for B-cell lymphoma after CAR-T therapy
This trial tests if the drug epcoritamab can help people with B-cell lymphoma whose cancer showed only a partial response 30 days after CAR-T cell therapy. It compares epcoritamab to simply monitoring the condition.
Rochester, MinnesotaAges 18 years+ - NCT07052565Recruiting
CAR-T cell therapy for autoimmune diseases
This trial uses your own engineered immune cells (CAR-T cells) to treat severe autoimmune diseases like rheumatoid arthritis, lupus, Sjögren's syndrome, or systemic sclerosis that haven't improved with standard medicines. The goal is to see if this treatment can calm the immune system and reduce disease activity.
HefeiAges 18 years+ - NCT07072247RecruitingPhase 1
RN1201 injection for hard-to-treat antibody-mediated blood disorders
This trial tests a new injection called RN1201 for people with antibody-mediated diseases, specifically two types of blood disorders: platelet transfusion refractoriness (PTR) and immune thrombocytopenia (ITP) that haven't responded to standard treatments. The goal is to see if RN1201 can help control these conditions.
Suzhou, JiangsuAges 16–65 - NCT07493395RecruitingPhase 2
CAR T-cell therapy for severe systemic sclerosis
This trial tests whether a special type of immune cell therapy, called CAR T-cells, can help people with severe systemic sclerosis (a disease causing skin and organ hardening) that hasn't improved with standard treatments. The goal is to see if it can stop the disease from getting worse.
LilleAges 18–64 - NCT05995015RecruitingPhase 1
CD19-targeting T cells for B cell cancers
This trial tests a new type of immune cell therapy (4SCAR19U T cells) designed to attack B-cell cancers. It may be an option if your cancer has the CD19 protein and you haven't had a prior CAR-T treatment that failed.
Shenzhen, GuangdongAges 6 months–75 years - NCT06515626RecruitingEarly Phase 1
Modified t cells for multiple cancers
This trial tests a personalized cell therapy where your own immune cells are collected, modified to better attack cancer, and then returned to you. It is for people with various solid tumors and lymphomas whose cancer cells have specific markers.
Zhengzhou, HenanAges 18–75 - NCT06758713RecruitingPhase 1
Gene-therapy treatment for blood cancers: safety and early effects
This trial tests a new kind of gene therapy (fourth-generation CAR-T) for several types of blood cancers including lymphoma, leukemia, and myeloma. It aims to see if the treatment is safe and starts to work against the cancer.
Guangzhou, GuangdongAges 18–75 - NCT06104592RecruitingPhase 2
Radiation before CAR T-cell therapy for high-risk large B-cell lymphoma
This trial tests if giving radiation to all visible tumor sites before standard CAR T-cell therapy can improve outcomes for people with high-risk large B-cell lymphoma. You may be eligible if you have at least one large tumor (5 cm or bigger) that can be targeted with radiation.
Tampa, FloridaAges 18 years+ - NCT05038696RecruitingPhase 1
CAR T-cell treatment for hard-to-control B-ALL
This Phase 1 trial tests a personalized “CAR T” cell treatment for people with relapsed or treatment-resistant B-lymphoblastic leukemia (B-ALL). It may help the immune system find and kill leukemia cells, especially when leukemia has not responded to standard treatment.
SingaporeAges 6 months–80 years - NCT06352242Recruiting
Study of immune activity after CAR-T therapy for lymphoma
This study looks at a biological process called trogocytosis (when immune cells swap pieces of their outer coating) to see if it can help predict how well CAR-T cell therapy works for people with a type of lymphoma called diffuse large B-cell lymphoma.
MontpellierAges 18 years+ - NCT07361224RecruitingPhase 1
Combining CLS-015 with CAR-T for large B-cell lymphoma
This trial tests combining an experimental drug (CLS-015) with a standard CAR-T cell therapy for people with large B-cell lymphoma whose disease is stable or progressing. It aims to see if the combination is safe and might improve treatment outcomes.
Tel AvivAges 18 years+ - NCT06834529RecruitingPhase 1/Phase 2
CAR-T cell therapy for returning B-cell leukemia or lymphoma
This trial tests a new type of immune cell therapy (CAR-T cells) designed to target and destroy leukemia or lymphoma cells that carry the CD19 or CD22 marker. It is for people whose cancer has not responded to other treatments or has returned.
Beijing, Beijing MunicipalityAges 14–75 - NCT07403097RecruitingPhase 1
CD19 CAR-T therapy for refractory lupus
This trial tests whether a personalized cell therapy called CD19 CAR-T can help people with hard-to-treat lupus (SLE). The treatment uses your own immune cells that have been modified to attack faulty B cells, which are involved in lupus. It is for patients who have moderate to severe disease despite trying multiple standard treatments.
ChongqingAges 5 years+ - NCT04107285Recruiting
Study brain changes in people with lymphoma after CAR T
This study looks at how thinking and brain function change over time in people with lymphoma who receive CAR T therapy. It may help doctors understand side effects and better support patients during and after treatment.
New York, New YorkAges 18 years+ - NCT06707259RecruitingPhase 1
Cord blood CAR NK cells for B-cell lymphoma
This trial tests a new treatment using immune cells from cord blood, called CAR NK cells, to fight certain types of B-cell lymphoma that have come back or not responded to other treatments. It is designed for people who have tried at least two prior therapies.
Hangzhou, ZhejiangAges 18–75 - NCT07248163Recruiting
Universal CAR-T cell therapy for non-Hodgkin lymphoma
This trial tests a universal CAR-T cell therapy for patients with non-Hodgkin lymphoma whose cancer cells have CD19 on their surface. It might help if standard treatments have not worked.
ShanghaiAges 18 years+ - NCT05077527RecruitingPhase 1
CAR-T treatment for HIV and aggressive B-cell lymphoma
This trial studies a lab-made immune cell treatment (CAR-T) for adults who have HIV and aggressive B-cell non-Hodgkin lymphoma that has come back or did not respond to prior treatment. It aims to see if the treatment can control the lymphoma safely in this specific group.
Duarte, CaliforniaAges 18 years+ - NCT06918912RecruitingPhase 2
Loncastuximab tesirine for lymphoma after CAR-T therapy
This trial tests a drug called loncastuximab tesirine for people with diffuse large B-cell lymphoma or high-grade B-cell lymphoma that has come back or not responded after CAR-T cell therapy. It aims to see if the drug can help when other treatments have stopped working.
Alessandria, ALESSANDRIAAges 18–99 - NCT05010564RecruitingPhase 1
TRICAR-ALL CAR-T treatment for tough childhood leukemia
This Phase 1 trial tests a customized CAR-T cell therapy for children and young adults with B-cell acute lymphoblastic leukemia (B-ALL) that keeps coming back or doesn’t respond to treatment. It aims to find a safer and effective way to control leukemia by targeting specific markers on the leukemia cells.
Houston, TexasAges 1–25 - NCT06532643RecruitingEarly Phase 1
CAR-T cells targeting CD20 and CD30 for relapsed lymphoma
This trial tests a new CAR-T cell therapy that targets two proteins (CD20 and CD30) on lymphoma cells. It is for people whose lymphoma has come back or not responded to other treatments, including previous stem cell transplants. The goal is to see if this treatment is safe and helps shrink or control the lymphoma.
Hefei, AnhuiAges 14–70 - NCT04440436RecruitingPhase 1/Phase 2
IM19 study for relapsed or refractory non-Hodgkin lymphoma
This trial tests whether IM19 can safely and effectively treat non-Hodgkin lymphoma that has come back or did not respond to prior treatment. It is for adults with certain lymphoma markers and good overall functioning.
Beijing, Beijing MunicipalityAges 18 years+
Common questions
- Are there clinical trials studying CD19 CAR-T cells?
- Yes. Clin2 currently lists 195 recruiting studies that include CD19 CAR-T cells, drawn from the U.S. registry and rewritten for real people so you can see what each is testing and who it's for.
- How do I know if I qualify for a CD19 CAR-T cells trial?
- Each study lists its own eligibility criteria — rules about condition, age, and prior treatments. On every Clin2 trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Is CD19 CAR-T cells an approved treatment?
- A drug being studied in a trial may be investigational (still being tested) or already approved and being studied for a new use. Each study page explains what phase it's in. Clin2 does not provide medical advice — talk with your doctor about whether CD19 CAR-T cells or a specific trial is right for you.
Related treatments
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. A drug appearing here is being studied in a trial and may be investigational. Talk with your doctor about whether a specific treatment or trial is right for you.